Schmerztherapiezentrum Brau Michel
- Address
- lock Available on a paid plan
Pathological Conditions and Pain Research
At Schmerztherapiezentrum Brau Michel in Osnabrück, clinical research focuses on pathological conditions, signs and symptoms with a strong emphasis on chronic pain. The studies are centered on evaluating whether new treatment approaches can help improve everyday pain control and patient comfort.
- Chronic pain due to diabetic polyneuropathy
- Chronic pain from traumatic or post-operative peripheral neuropathy
- Chronic pain linked to central neuropathy
- Chronic back pain
This work is aimed at testing the effectiveness and tolerability of new add-on therapy options for people living with persistent pain conditions.
Neuropathic Pain Studies
The center’s research portfolio includes multiple trials in neuropathic pain, covering both peripheral and central causes of long-lasting discomfort. These studies are designed to better understand how treatment can support patients whose pain is related to nerve damage or dysfunction.
- Diabetic polyneuropathy as a cause of chronic pain
- Peripheral neuropathy after trauma or surgery
- Central neuropathy of different origins
The main purpose is to assess whether a new therapy can provide meaningful relief as an add-on treatment in these difficult-to-manage conditions.
Chronic Back Pain Research
Another key area at the Center for Pain Therapy is chronic back pain, a common condition that can significantly affect mobility and quality of life. The trial activity here is focused on finding better ways to reduce persistent pain and improve daily functioning.
- Persistent back pain management
- Evaluation of symptom relief in long-term pain
- Assessment of treatment benefit in routine care settings
These studies are part of a broader effort to test new supportive therapies for people with ongoing pain symptoms.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 1 therapeutic areas and 15 of 25 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Apurano Pharmaceuticals GmbH4trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Schmerztherapiezentrum Brau Michel
lock Showing 1 of 4 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Tolerability of AP707 in Patients with Chronic Back Pain | Apurano Pharmaceuticals GmbH | Phase III | Not Recruiting | Nov 2023 | Mar 2026 |
IMP list
lock Showing 1 of 25 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Adezunap | 4 | Unknown | 2023-11-02 | 2023-11-02 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.